Payment overview · 2025
General Payments
$775.01
25 reported records · 13 companies
Healthcare provider profile · identity verified
Bethany C Vrouhas, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CHELMSFORD, MA · NPI 1417403650
Verified facts
What the public records show
CMS Open Payments records show Bethany C Vrouhas, NP received $775.01 in general payments during 2025 across 25 reported records.
Lilly USA, LLC accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.42 | 20.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.57 | 17.8% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $98.28 | 12.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $83.61 | 10.8% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.24 | 8.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.09 | 6.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.22 | 4.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.01 | 3.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.09 | 3.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $25.83 | 3.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.19 | 3.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.61 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.85 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $775.01 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.57 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $136.18 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $98.28 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $83.61 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $62.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $47.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.09 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
175 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 407 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 69 |
| Sertraline Hcl | Sertraline Hcl | 353 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 60 |
| Trazodone Hcl | Trazodone Hcl | 313 | 54 |
| Lisinopril | Lisinopril | 312 | 55 |
| Donepezil Hcl | Donepezil Hcl | 287 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 228 | 33 |
| Furosemide | Furosemide | 216 | 50 |
| Mirtazapine | Mirtazapine | 176 | 28 |
| Eliquis | Apixaban | 175 | 31 |
| Losartan Potassium | Losartan Potassium | 155 | 29 |
| Memantine Hcl | Memantine Hcl | 135 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 131 | 22 |
| Omeprazole | Omeprazole | 129 | 27 |
| Simvastatin | Simvastatin | 112 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 23 |
| Gabapentin | Gabapentin | 97 | 24 |
| Atenolol | Atenolol | 95 | 15 |
| Olanzapine | Olanzapine | 93 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 14 |
| Finasteride | Finasteride | 80 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 16 |
| Famotidine | Famotidine | 75 | 16 |
| Tramadol Hcl | Tramadol Hcl | 75 | 28 |
| Xarelto | Rivaroxaban | 75 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 17 |
| Metformin Hcl | Metformin Hcl | 64 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 62 | suppressed |
| Lorazepam | Lorazepam | 61 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 14 |
| Prednisone | Prednisone | 56 | 17 |
| Alendronate Sodium | Alendronate Sodium | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 41 |
| Alprazolam | Alprazolam | 48 | 15 |
| Loperamide | Loperamide Hcl | 47 | 19 |
| Midodrine Hcl | Midodrine Hcl | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 33 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 12 |
| Digoxin | Digoxin | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Nystatin | Nystatin | 31 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | 12 |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $775.01 · 25 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, MOUNJARO, NUPLAZID, Ozempic, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error